Literature DB >> 29928676

Nod-Like Receptor Pyrin-Containing Protein 6 (NLRP6) Is Up-regulated in Ileal Crohn's Disease and Differentially Expressed in Goblet Cells.

Nicole Ranson1, Mark Veldhuis2,3, Brent Mitchell2,3, Scott Fanning2,3, Anthony L Cook4, Dale Kunde1, Rajaraman Eri1.   

Abstract

Entities:  

Keywords:  CD, Crohn's disease; GC, goblet cell; IL, interleukin; PPAR, peroxisome proliferator-activated receptor; UC, ulcerative colitis

Year:  2018        PMID: 29928676      PMCID: PMC6007817          DOI: 10.1016/j.jcmgh.2018.03.001

Source DB:  PubMed          Journal:  Cell Mol Gastroenterol Hepatol        ISSN: 2352-345X


× No keyword cloud information.
A contributing factor in the development of ulcerative colitis (UC) and Crohn’s disease (CD) is aberrant signaling of the innate immune complex known as the inflammasome. The inflammasome regulates the production of interleukin (IL)1β and drives downstream inflammatory pathways. In this study of human tissue (ethics approval: H11930), we provide evidence for the disease-specific up-regulation of NLRP6 transcript and protein in ileal CD and describe an NLRP6-expressing goblet cell (GC) located predominantly in the upper portion of the intestinal crypt. Patient demographic details are provided in Supplementary Table 1.
Supplementary Table 1

Demographic Data for Study Participants

Patient categoryPatients, nAge, ySexDisease duration, y
Control patients2057 ± 1411 F, 9 M-
Paired UCa3050 ± 1816 F, 14 M11 ± 12
Quiescent UC only1049 ± 116 F, 4 M15 ± 11
Active UC only439 ± 212 F, 2 M11 ± 13
Paired ileal CDa641 ± 162 F, 4 M12 ± 8
Active ileal CD only1281 M15
Paired colonic CDa946 ± 154 F, 5 M8 ± 4
Active colonic CD only1461 F11
Quiescent CD (includes ileal CD and colonic CD) only420 ± 73 F, 1 M9 ± 14

NOTE. All data are shown as means ± SD. The disease duration at the time of biopsy is shown for each group as the mean value ± SD. The average onset of disease can be calculated by subtracting the disease duration from the average age of the patient. Inflammatory bowel disease patients comprised 65 of the total 85 participants, and, of these, 35 were women and 30 were men. The mean age of inflammatory bowel disease patients providing paired biopsy specimens was slightly younger for the CD group (44 ± 16 y) than the UC group (50 ± 18 y). The mean age of the control group was 57 ± 14 years and comprised 11 women and 9 men.

F, females; M, males.

Patients had biopsy specimens taken from quiescent disease and active disease regions.

By using paired quiescent and active biopsy specimens from UC and CD patients we found that the expression of NLRP6 increased with disease activity. In ileal CD we report a 131-fold (P < .001) increase in NLRP6 expression compared with a 3.9-fold (P = .03) increase in colonic CD (Figure 1A). The increase in IL1β expression was concomitant with increased messenger RNA levels of other inflammasome-related genes such as NLRP1, NLRP3, NLRC4, NLRP12, and AIM2 (Figure 1B and Supplementary Figure 1A and B), suggesting IL1β maturation by inflammasome activation is not solely NLRP6-dependent.
Figure 1

The effect of disease activity and rosiglitazone treatment on the expression of NLRP6-related genes. (A–D) Paired colon biopsy specimens from quiescent (q) and active disease (a) in ileal CD (n = 6), colonic CD (n = 9), and UC patients (n = 30). Relative gene expression of individual biopsy specimens expressed as log10-fold change. Horizontal lines indicate the median relative expression and error bars represent the interquartile ranges. (E and F) Gene expression of NLRP6 and MUC2 in LS174T cells treated with rosiglitazone (5–50,000 nmol/L). Levels are relative to ethanol-treated control cells. Data are expressed as means ± SEM of 3 independent experiments performed in duplicate. The significance threshold was P < .05. Un, unstimulated.

Supplementary Figure 1

Targeted RNA-sequencing analysis of inflammasome-related genes in CD biopsy specimens. (A) Targeted RNA-sequencing analysis of ileal CD biopsy specimens (n = 4) during active disease. Gene expression results are expressed as log 2 (fold change), normalized to housekeeping genes and relative to a normal control group (n = 4), which is indicated by the dotted vertical line. Up-regulated genes are shown as magenta, down-regulated genes are shown as black. (B) Targeted RNA-sequencing analysis of colonic CD biopsy specimens (n = 4) during active disease. Gene expression results are expressed as log 2 (fold change), normalized to housekeeping genes and relative to a normal control group (n = 4), which is indicated by the dotted vertical line. Up-regulated genes are shown as magenta, down-regulated genes are shown as black. NOD, nucleotide-binding oligomerization domain containing.

The effect of disease activity and rosiglitazone treatment on the expression of NLRP6-related genes. (A–D) Paired colon biopsy specimens from quiescent (q) and active disease (a) in ileal CD (n = 6), colonic CD (n = 9), and UC patients (n = 30). Relative gene expression of individual biopsy specimens expressed as log10-fold change. Horizontal lines indicate the median relative expression and error bars represent the interquartile ranges. (E and F) Gene expression of NLRP6 and MUC2 in LS174T cells treated with rosiglitazone (5–50,000 nmol/L). Levels are relative to ethanol-treated control cells. Data are expressed as means ± SEM of 3 independent experiments performed in duplicate. The significance threshold was P < .05. Un, unstimulated. Interestingly, the expression of IL18 remained constant despite variations in NLRP6 expression (Figure 1C). Mouse models have indicated discrepancies regarding the association of NLRP6 with the production of IL18. For example, Nlrp6 deficiency has been associated with low levels of IL18 and the induction of intestinal IL18 has been shown to be NLRP6-dependent. However, Normand et al reported no NLRP6-dependent changes in the transcript abundance of IL18 in tumoral and nontumoral biopsy specimens procured from Nlrp6+/+ and Nlrp6-/- mice. In agreement with Normand et al, this study reports no change in the expression of IL18 despite localized NLRP6 expression in inflamed human CD or UC biopsy tissue, suggesting IL18 expression is not NLRP6-dependent. NLRP6 was found to be highly expressed in colon biopsy specimens from active ileal CD patients and localized to the epithelial cell layer, myofibroblasts, neutrophils, and monocytic lineage cells of the lamina propria (Supplementary Figure 2). Previously, NLRP6 expression in the normal human gut has been described as restricted to the duodenum, jejunum/ileum, and absent from the colon. In contrast, murine Nlrp6 is highly expressed in the small and large intestine.
Supplementary Figure 2

Representative immunohistochemistry (IHC) images and quantification of NLRP6 and MUC2 expression in left colon biopsies. All biopsies were paraffin embedded, cut into 3-5 μm sections and incubated with NLRP6 (NBP2-31372, Novus Biologicals, Littleton, CA) and MUC2 (H:300 sc-15334, Santa Cruz Biotechnologies, TX). Images were captured using DP21 microscope camera (Olympus Australia, Melbourne, Australia) attached to an IX71 microscope (Olympus). Images are 400X and scale bar = 50 μm. (A) Quantitative (Quant.) analysis of DAB staining in paraffin embedded left colon mucosal biopsies as analysed by IHC. (B) NLRP6 expression in sections from normal colon (number of images analysed = 18), active UC (n = 43), remission UC (Rem. UC, n = 20), active ileal CD (n = 34), active colonic CD (n = 18) and remission CD (Rem. CD, n = 12). (C) MUC2 expression in sections from normal colon (n = 20), active UC n = 62), remission UC (n = 20), active ileal CD (n = 24), active colonic CD (n = 30), and remission CD (n = 30). The optical intensity of DAB staining was determined using ImageJ software. All data are presented as mean ± standard deviation. Statistical significance was evaluated using Dunn's multiple comparison One-way ANOVA and the significance threshold was P < .05. Here we present contrasting expression patterns for both NLRP6 and MUC2. In active ileal CD, NLRP6 expression is localised to the epithelial cell layer, myofibroblasts, neutrophils and monocytic linage cells residing in the lamina propria. In active UC NLRP6 expression is limited to lamina propria immune cells and absent for the epithelial cell layer. Interestingly, in the normal colon, moderate cytoplasmic NLRP6 expression was present in the epithelial cell layer and scattered within the lamina propria cells. Quantitative analysis of NLRP6 IHC staining confirms the high NLRP6 expression observed in ileal CD (active ileal CD vs active colonic CD, P < .001; active ileal CD vs remission CD, P < .001). MUC2 expression in active IBD and the normal colon is highly variable in distribution and depth. In active CD, both colonic and ileal the expression of MUC2 is increased while in UC it is reduced. The reduced MUC2 expression in active UC is well established and consistent with previous studies in human derived material.[2-4] Interestingly, there was no change in MUC2 expression in ileal and colonic CD despite the increased NLRP6 in ileal CD. Quantitatively, the expression of MUC2 in active ileal CD was greater than in active UC (P = .002).

In mice, Nlrp6 has been shown to regulate goblet cell mucin production and secretion,5, 6 and direct self-renewal and proliferation of epithelial cells. By using immunofluorescence confocal microscopy we sort to ascertain the spatial relationship of NLRP6 to the major mucin protein MUC2 and the epithelial cell marker E-cadherin. The fluorescence signal of NLRP6 was not present in the MUC2 granules (Figure 2A and C), but overlapped the fluorescence signal of E-cadherin (Figure 2B and D). Both myofibroblasts and E-cadherin contribute to epithelial cell structure and renewal. Colonic myofibroblasts are a major source of modulators of the Wnt signaling pathway, which governs approximately 80 genes involved in the differentiation, proliferation, and upward migration of gastrointestinal epithelial cells. Cellular adhesion, maturation, and the correct placement of Paneth and goblet cells is dependent on the proper expression of E-cadherin. Given the high expression of NLRP6 in colonic myofibroblasts and the tight association with E-cadherin, one can speculate that NLRP6 may play a role in epithelial cell positioning and migration.
Figure 2

The differential NLRP6 expression in ileal CD goblet cells and overlap of NLRP6/E-cadherin fluorescence signals. Representative immunofluorescence confocal images of NLRP6 (magenta), MUC2 (green), in (A) active ileal CD colon biopsy specimens and (B) normal colon biopsy specimens. Solidline indicates goblet cells with high NLRP6 expression. Dashed line indicates goblet cell with minimal NLRP6 expression. Representative immunofluorescence confocal images of NLRP6 (magenta) and E-cadherin (green) in (B) active ileal CD biopsy specimens and (D) normal colon biopsy specimens. Spatial profiling is indicated by the straight dotted line. Nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI, blue), original magnification for all images: 400×. Scale bars: 50 μm. Ecad, E-cadherin.

The differential NLRP6 expression in ileal CD goblet cells and overlap of NLRP6/E-cadherin fluorescence signals. Representative immunofluorescence confocal images of NLRP6 (magenta), MUC2 (green), in (A) active ileal CD colon biopsy specimens and (B) normal colon biopsy specimens. Solidline indicates goblet cells with high NLRP6 expression. Dashed line indicates goblet cell with minimal NLRP6 expression. Representative immunofluorescence confocal images of NLRP6 (magenta) and E-cadherin (green) in (B) active ileal CD biopsy specimens and (D) normal colon biopsy specimens. Spatial profiling is indicated by the straight dotted line. Nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI, blue), original magnification for all images: 400×. Scale bars: 50 μm. Ecad, E-cadherin. In active ileal CD biopsy specimens, prominent NLRP6 expression was observed in a number of upper crypt GCs whereas other GCs remained NLRP6 negative (Figure 2A). In the murine system, Birchenough et al identified a sentinel goblet cell localized to the crypt opening that undergoes expulsion and compound exocytosis in an NLRP6-dependent manner. The expelled sentinel goblet cell triggered an intercellular signal via gap junctions that increased cytoplasmic Ca2+ and induced Muc2 secretion in adjacent responsive goblet cells. Interestingly, we found the production of MUC2 to be increased in active ileal CD and reduced in active UC (Supplementary Figures 2 and 3).
Supplementary Figure 3

Representative immunofluorescence images of MUC2 localization in normal colon, active UC, and active ileal and colonic CD. All biopsy specimens were taken from the left colon, paraffin-embedded, cut into 5-μm sections, incubated with MUC2 (H:300: sc15334, 1:200 dilution; Santa Cruz), and visualized using Alexa Fluor 647–conjugated goat anti-rabbit IgG (green). Nuclei were stained with Hoechst 33342 (4′,6-diamidino-2-phenylindole, blue). Scale bars: 100 μm for both the 100× and 400× magnification. Here, we present immunofluorescence microscopy images showing the variations in MUC2 architecture. In CD, the MUC2 granules are highly organized and this structural organization is lacking in active UC and in the normal colon. Furthermore, colonic crypts normally contain smaller goblet cell theca containing less MUC2 in the lower crypts and larger MUC2-filled theca in the upper crypt. However, in active ileal CD and active colonic CD we observed large tightly packed theca containing MUC2 granules along the entire crypt length, and the overcrowding of goblet cells often was associated with crypt distortion.

Transcriptional regulation of NLRP6 by peroxisome proliferator-activated receptor-γ (PPAR-γ) has been proposed based on the presence of binding sites for PPAR-γ and retinoid X receptor upstream of the promotor region of NLRP6.8, 9 We found the expression of PPAR-γ to be reduced in active UC and CD (Figure 1D), and that exposure of LS174T colonic epithelial cells to the PPAR-γ agonist rosiglitazone induced NLRP6 but repressed MUC2 expression (Figure 1E and F). Previously, the expression of PPAR-γ has been reported as reduced in active UC and comparable with normal colon in active CD. Taken altogether, our results suggest that MUC2 expression is independent of NLRP6 activity, however, there is insufficient evidence to suggest the negative regulation of NLRP6 by PPAR-γ. This study has been instrumental in highlighting inconsistencies in NLRP6 expression, IL18 processing, and MUC2 expression between murine models of chemically induced colitis and human inflammatory bowel disease. NLRP6 now can be regarded as an additional diagnostic tool for distinguishing ileal CD from colonic CD and terminal ileum involved UC. Future work needs to address if there is a therapeutic benefit in switching on NLRP6 in active UC or if disabling NLRP6 improves disease activity in ileal CD.
  13 in total

1.  Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis.

Authors:  R D Pullan; G A Thomas; M Rhodes; R G Newcombe; G T Williams; A Allen; J Rhodes
Journal:  Gut       Date:  1994-03       Impact factor: 23.059

2.  The human gastrointestinal tract-specific transcriptome and proteome as defined by RNA sequencing and antibody-based profiling.

Authors:  Gabriela Gremel; Alkwin Wanders; Jonathan Cedernaes; Linn Fagerberg; Björn Hallström; Karolina Edlund; Evelina Sjöstedt; Mathias Uhlén; Fredrik Pontén
Journal:  J Gastroenterol       Date:  2014-05-01       Impact factor: 7.527

3.  Comparative study of the intestinal mucus barrier in normal and inflamed colon.

Authors:  Alexander Swidsinski; Vera Loening-Baucke; Franz Theissig; Holger Engelhardt; Stig Bengmark; Stefan Koch; Herbert Lochs; Yvonne Dörffel
Journal:  Gut       Date:  2006-08-14       Impact factor: 23.059

4.  Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury.

Authors:  Sylvain Normand; Anne Delanoye-Crespin; Aude Bressenot; Ludovic Huot; Teddy Grandjean; Laurent Peyrin-Biroulet; Yves Lemoine; David Hot; Mathias Chamaillard
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-18       Impact factor: 11.205

5.  A sentinel goblet cell guards the colonic crypt by triggering Nlrp6-dependent Muc2 secretion.

Authors:  George M H Birchenough; Elisabeth E L Nyström; Malin E V Johansson; Gunnar C Hansson
Journal:  Science       Date:  2016-06-24       Impact factor: 47.728

6.  Correlations between colonic crypt mucin chemotype, inflammatory grade and Desulfovibrio species in ulcerative colitis.

Authors:  G Lennon; Á Balfe; N Bambury; A Lavelle; A Maguire; N G Docherty; J C Coffey; D C Winter; K Sheahan; P R O'Connell
Journal:  Colorectal Dis       Date:  2014-05       Impact factor: 3.788

7.  Developmental control of the Nlrp6 inflammasome and a substrate, IL-18, in mammalian intestine.

Authors:  Sarah L Kempster; Gusztav Belteki; Alison J Forhead; Abigail L Fowden; Robert D Catalano; Brian Y Lam; Ian McFarlane; D Stephen Charnock-Jones; Gordon C S Smith
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-11-18       Impact factor: 4.052

8.  NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis.

Authors:  Eran Elinav; Till Strowig; Andrew L Kau; Jorge Henao-Mejia; Christoph A Thaiss; Carmen J Booth; David R Peaper; John Bertin; Stephanie C Eisenbarth; Jeffrey I Gordon; Richard A Flavell
Journal:  Cell       Date:  2011-05-12       Impact factor: 41.582

9.  Microbiota-Modulated Metabolites Shape the Intestinal Microenvironment by Regulating NLRP6 Inflammasome Signaling.

Authors:  Maayan Levy; Christoph A Thaiss; David Zeevi; Lenka Dohnalová; Gili Zilberman-Schapira; Jemal Ali Mahdi; Eyal David; Alon Savidor; Tal Korem; Yonatan Herzig; Meirav Pevsner-Fischer; Hagit Shapiro; Anette Christ; Alon Harmelin; Zamir Halpern; Eicke Latz; Richard A Flavell; Ido Amit; Eran Segal; Eran Elinav
Journal:  Cell       Date:  2015-12-03       Impact factor: 41.582

10.  NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion.

Authors:  Marta Wlodarska; Christoph A Thaiss; Roni Nowarski; Jorge Henao-Mejia; Jian-Ping Zhang; Eric M Brown; Gad Frankel; Maayan Levy; Meirav N Katz; William M Philbrick; Eran Elinav; B Brett Finlay; Richard A Flavell
Journal:  Cell       Date:  2014-02-27       Impact factor: 41.582

View more
  7 in total

Review 1.  Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome.

Authors:  Ziying Zhang; Haosheng Tang; Peng Chen; Hui Xie; Yongguang Tao
Journal:  Signal Transduct Target Ther       Date:  2019-10-12

Review 2.  Physiological and pathophysiological functions of NLRP6: pro- and anti-inflammatory roles.

Authors:  Diego Angosto-Bazarra; Cristina Molina-López; Pablo Pelegrín
Journal:  Commun Biol       Date:  2022-06-01

Review 3.  Therapeutic implications of inflammasome in inflammatory bowel disease.

Authors:  Vishal Khatri; Ramaswamy Kalyanasundaram
Journal:  FASEB J       Date:  2021-05       Impact factor: 5.834

Review 4.  The protective roles of NLRP6 in intestinal epithelial cells.

Authors:  Jiuheng Yin; Baifa Sheng; Kunqiu Yang; Lihua Sun; Weidong Xiao; Hua Yang
Journal:  Cell Prolif       Date:  2018-12-04       Impact factor: 6.831

Review 5.  The role of goblet cells in viral pathogenesis.

Authors:  Valerie Cortez; Stacey Schultz-Cherry
Journal:  FEBS J       Date:  2021-02-09       Impact factor: 5.622

Review 6.  Nuclear Receptors as Multiple Regulators of NLRP3 Inflammasome Function.

Authors:  Ahmad Alatshan; Szilvia Benkő
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

Review 7.  Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies.

Authors:  Yuting Lu; Xiangliang Yuan; Miao Wang; Zhihao He; Hongzhong Li; Ji Wang; Qin Li
Journal:  J Hematol Oncol       Date:  2022-04-29       Impact factor: 23.168

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.